These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 19744163)
1. Effect of octreotide on polycystic liver volume. van Keimpema L; Drenth JP Liver Int; 2010 Apr; 30(4):633-4. PubMed ID: 19744163 [No Abstract] [Full Text] [Related]
2. Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial. Chrispijn M; Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Drenth JP J Hepatol; 2013 Jul; 59(1):153-9. PubMed ID: 23499726 [TBL] [Abstract][Full Text] [Related]
3. Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease. van Aerts RMM; Kievit W; D'Agnolo HMA; Blijdorp CJ; Casteleijn NF; Dekker SEI; de Fijter JW; van Gastel M; Gevers TJ; van de Laarschot LFM; Lantinga MA; Losekoot M; Meijer E; Messchendorp AL; Neijenhuis MK; Pena MJ; Peters DJM; Salih M; Soonawala D; Spithoven EM; Visser FW; Wetzels JF; Zietse R; Gansevoort RT; Drenth JPH; Gastroenterology; 2019 Aug; 157(2):481-491.e7. PubMed ID: 31022403 [TBL] [Abstract][Full Text] [Related]
4. Somatostatin analogues reduce liver volume in polycystic liver disease. van Keimpema L; de Man RA; Drenth JP Gut; 2008 Sep; 57(9):1338-9. PubMed ID: 18719151 [No Abstract] [Full Text] [Related]
5. Lanreotide Reduces Liver Volume, But Might Not Improve Muscle Wasting or Weight Loss, in Patients With Symptomatic Polycystic Liver Disease. Temmerman F; Ho TA; Vanslembrouck R; Coudyzer W; Billen J; Dobbels F; van Pelt J; Bammens B; Pirson Y; Nevens F Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2353-9.e1. PubMed ID: 26073493 [TBL] [Abstract][Full Text] [Related]
6. Octreotide therapy in dumping syndrome: Analysis of long-term results. Didden P; Penning C; Masclee AA Aliment Pharmacol Ther; 2006 Nov; 24(9):1367-75. PubMed ID: 17059518 [TBL] [Abstract][Full Text] [Related]
7. Twenty-four hour prophylaxis with increased dosage of octreotide reduces the incidence of post-ERCP pancreatitis. Thomopoulos KC; Pagoni NA; Vagenas KA; Margaritis VG; Theocharis GI; Nikolopoulou VN Gastrointest Endosc; 2006 Nov; 64(5):726-31. PubMed ID: 17055865 [TBL] [Abstract][Full Text] [Related]
8. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly. Turner HE; Thornton-Jones VA; Wass JA Clin Endocrinol (Oxf); 2004 Aug; 61(2):224-31. PubMed ID: 15272918 [TBL] [Abstract][Full Text] [Related]
9. Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease. Pisani A; Sabbatini M; Imbriaco M; Riccio E; Rubis N; Prinster A; Perna A; Liuzzi R; Spinelli L; Santangelo M; Remuzzi G; Ruggenenti P; Clin Gastroenterol Hepatol; 2016 Jul; 14(7):1022-1030.e4. PubMed ID: 26844873 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients With Severe Polycystic Liver Disease. Hogan MC; Masyuk T; Bergstralh E; Li B; Kremers WK; Vaughan LE; Ihrke A; Severson AL; Irazabal MV; Glockner J; LaRusso NF; Torres VE Mayo Clin Proc; 2015 Aug; 90(8):1030-7. PubMed ID: 26166166 [TBL] [Abstract][Full Text] [Related]
11. [Indications for the use of somatostatin and octreotide in digestive pathology]. Zan S; Roy L; Zanon C; Mobiglia A; Mussa B; Raviola P; Mormile C; Ballario R; Giustetto A Minerva Gastroenterol Dietol; 1996 Jun; 42(2):107-14. PubMed ID: 8962905 [TBL] [Abstract][Full Text] [Related]
12. Safety of subcutaneous octreotide in patients with sulfonylurea-induced hypoglycemia and congestive heart failure. Vallurupalli S Ann Pharmacother; 2010 Feb; 44(2):387-90. PubMed ID: 20118140 [TBL] [Abstract][Full Text] [Related]
13. Global improvement of systemic scleroderma under long-term administration of octreotide. Descamps V; Duval X; Crickx B; Bouscarat F; Coffin B; Belaich S Eur J Dermatol; 1999 Sep; 9(6):446-8. PubMed ID: 10491499 [TBL] [Abstract][Full Text] [Related]
14. Treatments of various otolaryngological cystic diseases by OK-4321: its indications and limitations. Ohta N; Fukase S; Suzuki Y; Ishida A; Aoyagi M Laryngoscope; 2010 Nov; 120(11):2193-6. PubMed ID: 20938959 [TBL] [Abstract][Full Text] [Related]
15. Long-acting octreotide as rescue therapy in chronic bleeding from gastrointestinal angiodysplasia. Scaglione G; Pietrini L; Russo F; Franco MR; Sorrentini I Aliment Pharmacol Ther; 2007 Sep; 26(6):935-42. PubMed ID: 17767478 [TBL] [Abstract][Full Text] [Related]
16. Randomised trial of octreotide for long term management of cirrhosis after variceal hemorrhage. Sheikh RA; Trudeau WL Gastrointest Endosc; 1998 Sep; 48(3):328-30. PubMed ID: 9744619 [No Abstract] [Full Text] [Related]
17. A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study. Spahr L; Giostra E; Frossard JL; Morard I; Mentha G; Hadengue A Am J Gastroenterol; 2007 Jul; 102(7):1397-405. PubMed ID: 17488248 [TBL] [Abstract][Full Text] [Related]
18. Octreotide inhibits pancreatic exocrine secretion and prevents pancreatoenterostomy leakage. Nakatsuka A; Yamaguchi K; Chijiiwa K; Tanaka M Int Surg; 2000; 85(2):124-9. PubMed ID: 11071328 [TBL] [Abstract][Full Text] [Related]
19. Continuous subcutaneous octreotide in gastrointestinal cancer patients: pain control and beta-endorphin levels. Befon S; Mystakidou K; Lyra M; Tubanakis N; Vlahos L Anticancer Res; 2000; 20(5C):4039-46. PubMed ID: 11268498 [TBL] [Abstract][Full Text] [Related]
20. Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data. Gevers TJ; Inthout J; Caroli A; Ruggenenti P; Hogan MC; Torres VE; Nevens F; Drenth JP Gastroenterology; 2013 Aug; 145(2):357-65.e1-2. PubMed ID: 23665274 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]